Results 51 to 60 of about 30,028 (235)

FAMILIAL HETEROZYGOUS HYPERCHOLESTEROLEMIA: A CASE REPORT

Wiadomości Lekarskie, 2019
Іntroduction: Familial hypercholesterolemia (FH) is an autosomal dominant disorder, caused by the defect of the gene, encoding the structure and function of the receptor for the apoprotein B/E. Patients with FH are predisposed to premature development of atherosclerosis and clinically manifested forms of cardiovascular diseases, in particular coronary ...
Vyacheslav М, Zhdan, Yevdokiia М, Kitura, Maryna Yu, Babanina, Oksana Ye, Kitura, Maksym V, Tkachenko   +4 more
openaire   +2 more sources

Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia?

, 2015
A previous report suggested that 88% of individuals in the general population with total cholesterol (TC) > 9.3 mmol/L have familial hypercholesterolaemia (FH). We tested this hypothesis in a cohort of 4896 UK civil servants, mean (SD) age 44 (±6) years,
Humphries, S.E., Kivimaki, M, Boustred, C, Boustred, C., Kumari, M., Kivimaki, M., Humphries, SE, Futema, M., Futema, M, Kumari, M   +9 more
core   +1 more source

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in the real ...
Koutaro Yokote, Junya Ako, Kazuo Kitagawa, Nobuhiro Osada, Feng Sheng, Masae Sonoda, Tamio Teramoto   +6 more
doaj   +1 more source

Efficacy and Safety of Alirocumab as Add-on Therapy in High–Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg)::Design and Rationale of the ODYSSEY OPTIONS Studies [PDF]

, 2014
The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal ...
Peter H. Jones, Robinson, Jennifer G., Hanotin, Corinne, Du, Yunling, Jones, Peter H., Harold E. Bays, Corinne Hanotin, Yunling Du, Colhoun, Helen M., Donahue, Stephen, Jennifer G. Robinson, Helen M. Colhoun, Stephen Donahue, Bays, Harold E.   +13 more
core   +1 more source

Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia

Reviews in Cardiovascular Medicine, 2016
Familial hypercholesterolemia (FH) is an autosomal co-dominant disorder marked by extremely high low-density lipoprotein (LDL) cholesterol levels and concomitant premature vascular disease. FH is caused by mutations that most commonly affect three genes integrally involved in the LDL receptor's ability to clear LDL particles from the circulation ...
Seth J, Baum, Daniel, Soffer, P, Barton Duell   +2 more
openaire   +2 more sources

Salivary cholesterol level does not reflect cholesterolemia in children with heterozygous familial hypercholesterolemia

, 2023
International audienceObjectivesHeterozygous familial hypercholesterolemia is a common genetic disease responsible for premature atherosclerosis. Therefore, early diagnosis and treatment are recommended to reduce cardiovascular risk.
Croyal, Mikael, Mathilde Di Filippo, Pierre Poinsot, Cédric Sage, Noel Peretti, Brignot, Hélène, Séverine Nony, Peretti, Noel, Poinsot, Pierre, Hélène Brignot, Nony, Séverine, Moulin, Philippe, Marianne Fricaudet, Feron, Gilles, Peron, Marie Anais, Rémi Duclaux Loras, Duclaux Loras, Rémi, Marie Anais Peron, Sybil Charriere, Mikael Croyal, Sage, Cédric, Di Filippo, Mathilde, Fricaudet, Marianne, Philippe Moulin, Gilles Feron, Charriere, Sybil   +25 more
core   +1 more source

Establishment of a human induced pluripotent stem cell line from a patient with familial hypercholesterolemia carrying a frameshift mutation in LDLR gene

Stem Cell Research
Familial hypercholesterolemia is an autosomal dominant genetic disorder that often leads to abnormally high cholesterol levels in the body, which is closely related to early-onset coronary heart disease.
Yongjuan Ruan, Xiaowei Li, Jianzeng Dong, Youjian Zhang   +3 more
doaj   +1 more source

Lipoprotein (a) levels in children with heterozygous familial hypercholesterolemia [PDF]

КардиоСоматика
BACKGROUND: Recent studies show that lipoprotein (a), or Lp(a), plays a specific role in the development of atherosclerosis. Lp(a) promotes atherogenesis by increasing production of pro-inflammatory cytokines and depositing on the arterial wall.
Liliya F. Galimova, Dinara I. Sadykova, Evgeniia S. Slastnikova, Chulpan D. Khaliullina, Karina R. Salakhova   +4 more
doaj   +1 more source

FEMORAL ATHEROSCLEROSIS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA. INFLUENCE OF THE GENETIC DEFECT [PDF]

Atherosclerosis Supplements, 2008
Objective— The purpose of this study was to assess femoral atherosclerosis by ultrasound in patients with molecularly defined heterozygous familial hypercholesterolemia (FH) in comparison with matched control subjects and in relation to mutational class in the LDL receptor and apolipoprotein B (APOB)
Mireia, Junyent, Rosa, Gilabert, Daniel, Zambón, Miguel, Pocoví, Miguel, Mallén, Montserrat, Cofán, Isabel, Núñez, Fernando, Civeira, Diego, Tejedor, Emilio, Ros   +9 more
openaire   +3 more sources

Modern strategy of diagnosis and treatment of children with heterozygous familial hypercholesterolemia

Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics), 2020
Familial heterozygous hypercholesterolemia Is an autosomal dominant disease characterized by high levels of low-density lipoprotein cholesterol, leading to an atherosclerotic vascular damage in children and myocardial infarction in 20 -30 years-old ...
I. Leontyeva
semanticscholar   +1 more source